撰文丨王聪编辑丨王多鱼排版丨水成文CAR-T 细胞疗法在血液类癌症中取得了令人瞩目的治疗效果，然而，癌细胞面对 CAR-T 细胞的杀伤，会通过抗原调变（antigen modulation）减少表面靶抗原（例如 CD19）的表达，从而逃逸杀伤，导致治疗的耐药性和复发，这也是 CAR-T 细胞疗法面临的最严峻的挑战之一。给CAR ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

The mechanical properties of tissue matrix are crucial for maintaining cell health and function. With aging, tissue matrix loses its mechanical integrity and exhibits altered biophysical properties, ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...